Pathway analysis using GRB2, a significantly connected and downregulated protein as the focus. by Eiman Y. Ibrahim (10731078)

Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

Significantly Enriched Pathways. by Jiyong Zhang (2498740)

Subjects:

The level of miRNA 221 in the myocardium of MIRI mice was decreased. by Hongyu Li (1332669)

Subjects:

Decrease of injuries. by Petr Fulin (8380320)

Subjects:

Map of Pakistan with marked Punjab province. by Sumaira Sumaira (21453523)

Flowchart of the participants’ progress in the study. by Diego T. Dias (3151332)

Decrease of admissions and lead diagnoses. by Petr Fulin (8380320)

Subjects:

Diagram showing progression to carotid artery stenosis after radiotherapy, including significant and non-significant lesions, clinical presentation, and treatment. by Nawaphan Taengsakul (20642371)

Survival outcomes are improved in canine DLBCL patients receiving chemoimmunotherapy who progress after 90 days. by Katherine Dittrich (16884275)

Sensitivity analyses of seroprevalence with the largest sample size study omitted. by Yu Zhou (89766)

Coagulation parameters in patients receiving and not receiving ancoagulant (AK) therapy at admission. by Ekaterina M. Koltsova (5464523)

Chronic colitis induces marked changes in protein expression in the adult heart and blood. by Yanbo Tang (11457519)

Progression-free survival. by Issei Saeki (741994)

“…Patients with AFP ≥ 400 ng/mL had a significantly higher OR rate than those with < 400 ng/mL (28.2 vs. 8.5%, <i>p</i> = 0.011), and there was no significant difference in progression-free survival (PFS) between the two groups. …”

Significant relationships between QOL measures on infusion day and day 7. by Jordan K. Abbott (8934239)

Subjects:

Generalizable improvement of QOL measures on day 7 vs. infusion day. by Jordan K. Abbott (8934239)

Subjects:

Coagulation parameters in patients receiving and not receiving antithrombotic (ATT) therapy at admission (with anticoagulants or antiplatelet agents). by Ekaterina M. Koltsova (5464523)

Time to progression towards ARDS and length of hospital stay of patients with baseline SuPAR ≥ 6 ng/mL who received and did not receive anakinra. by Francesco Vladimiro Segala (9338937)

CONSORT flow diagram of the progress of RCT. by Kavinda T. Malwanage (14135177)

Progression-free survival by baseline AFP. by Issei Saeki (741994)